Related references
Note: Only part of the references are listed.Glyoxalase 1 sustains the metastatic phenotype of prostate cancer cells via EMT control
Cinzia Antognelli et al.
JOURNAL OF CELLULAR AND MOLECULAR MEDICINE (2018)
HOXB8 promotes tumor metastasis and the epithelial-mesenchymal transition via ZEB2 targets in gastric cancer
Wen-Jin Ding et al.
JOURNAL OF CANCER RESEARCH AND CLINICAL ONCOLOGY (2017)
Valosin-containing protein (VCP) promotes the growth, invasion, and metastasis of colorectal cancer through activation of STAT3 signaling
Qianfeng Fu et al.
MOLECULAR AND CELLULAR BIOCHEMISTRY (2016)
STAT3 cooperates with Twist to mediate epithelial-mesenchymal transition in human hepatocellular carcinoma cells
Chuanhai Zhang et al.
ONCOLOGY REPORTS (2015)
Analysis of HOX Gene Expression Patterns in Human Breast Cancer
Ho Hur et al.
MOLECULAR BIOTECHNOLOGY (2014)
Establishment of a Predictive Genetic Model for Estimating Chemotherapy Sensitivity of Colorectal Cancer with Synchronous Liver Metastasis
Xingrong Lu et al.
CANCER BIOTHERAPY AND RADIOPHARMACEUTICALS (2013)
Identification of HOXB8 and KLK11 expression levels as potential biomarkers to predict the effects of FOLFOX4 chemotherapy
Shaotang Li et al.
FUTURE ONCOLOGY (2013)
Aberrant Expression of Posterior HOX Genes in Well Differentiated Histotypes of Thyroid Cancers
Monica Cantile et al.
INTERNATIONAL JOURNAL OF MOLECULAR SCIENCES (2013)
Epithelial to Mesenchymal Transition Promotes Breast Cancer Progression via a Fibronectin-dependent STAT3 Signaling Pathway
Nikolas Balanis et al.
JOURNAL OF BIOLOGICAL CHEMISTRY (2013)
HOXB7 as a Prognostic Factor and Mediator of Colorectal Cancer Progression
Wen-Ting Liao et al.
CLINICAL CANCER RESEARCH (2011)
Global Patterns of Cancer Incidence and Mortality Rates and Trends
Ahmedin Jemal et al.
CANCER EPIDEMIOLOGY BIOMARKERS & PREVENTION (2010)
Bevacizumab in combination with oxaliplatin-based chemotherapy as first-line therapy in metastatic colorectal cancer:: A randomized phase III study
Leonard B. Saltz et al.
JOURNAL OF CLINICAL ONCOLOGY (2008)
Overall survival of patients with advanced colorectal cancer correlates with availability of fluorouracil, irinotecan, and oxaliplatin regardless of whether doublet or single-agent therapy is used first line
A Grothey et al.
JOURNAL OF CLINICAL ONCOLOGY (2005)
A Randomized controlled trial of fluorouracil plus leucovorin, irinotecan, and oxaliplatin combinations in patients with previously untreated metastatic colorectal cancer
RM Goldberg et al.
JOURNAL OF CLINICAL ONCOLOGY (2004)
Pharmacogenetics and adverse drug reactions
UA Meyer
LANCET (2000)
Deregulated expression of homeobox-containing genes, HOXB6, B8, C8, C9, and Cdx-1, in human colon cancer cell lines
BZ Vider et al.
BIOCHEMICAL AND BIOPHYSICAL RESEARCH COMMUNICATIONS (2000)
Share Paper
